WO2024134524A1 - Matériau composite à base de verre bioactif et de phosphate de calcium amorphe et procédé pour sa production - Google Patents
Matériau composite à base de verre bioactif et de phosphate de calcium amorphe et procédé pour sa production Download PDFInfo
- Publication number
- WO2024134524A1 WO2024134524A1 PCT/IB2023/062999 IB2023062999W WO2024134524A1 WO 2024134524 A1 WO2024134524 A1 WO 2024134524A1 IB 2023062999 W IB2023062999 W IB 2023062999W WO 2024134524 A1 WO2024134524 A1 WO 2024134524A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acp
- particles
- composite material
- mbgn
- composite
- Prior art date
Links
- 239000002131 composite material Substances 0.000 title claims abstract description 119
- 238000000034 method Methods 0.000 title claims abstract description 23
- 239000001506 calcium phosphate Substances 0.000 title claims abstract description 19
- 235000011010 calcium phosphates Nutrition 0.000 title claims abstract description 19
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 title claims abstract description 19
- 230000008569 process Effects 0.000 title claims abstract description 18
- 239000005313 bioactive glass Substances 0.000 title claims abstract description 14
- 229910000389 calcium phosphate Inorganic materials 0.000 title claims abstract description 14
- 150000002500 ions Chemical class 0.000 claims abstract description 51
- 239000002245 particle Substances 0.000 claims abstract description 42
- 239000002105 nanoparticle Substances 0.000 claims abstract description 22
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 18
- 230000000395 remineralizing effect Effects 0.000 claims abstract description 12
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 11
- 238000005115 demineralization Methods 0.000 claims abstract description 8
- 210000004268 dentin Anatomy 0.000 claims abstract description 8
- 230000010478 bone regeneration Effects 0.000 claims abstract description 7
- 230000002328 demineralizing effect Effects 0.000 claims abstract description 7
- 239000011159 matrix material Substances 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 32
- 239000000243 solution Substances 0.000 claims description 26
- 229910052731 fluorine Inorganic materials 0.000 claims description 17
- 238000002156 mixing Methods 0.000 claims description 13
- 208000002925 dental caries Diseases 0.000 claims description 8
- 239000011777 magnesium Substances 0.000 claims description 8
- 229910052749 magnesium Inorganic materials 0.000 claims description 7
- 239000002244 precipitate Substances 0.000 claims description 7
- 229910052708 sodium Inorganic materials 0.000 claims description 7
- 239000001509 sodium citrate Substances 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- -1 chlorine ions Chemical class 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 210000000988 bone and bone Anatomy 0.000 claims description 5
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 5
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 5
- 239000011701 zinc Substances 0.000 claims description 5
- 229910052725 zinc Inorganic materials 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 239000010949 copper Substances 0.000 claims description 4
- 229910052802 copper Inorganic materials 0.000 claims description 4
- 239000002019 doping agent Substances 0.000 claims description 4
- 229910052742 iron Inorganic materials 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 4
- 229910052709 silver Inorganic materials 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052712 strontium Inorganic materials 0.000 claims description 4
- 159000000007 calcium salts Chemical class 0.000 claims description 3
- 150000005323 carbonate salts Chemical class 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 2
- 239000000920 calcium hydroxide Substances 0.000 claims description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 2
- 230000007547 defect Effects 0.000 claims description 2
- 238000000586 desensitisation Methods 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 239000007943 implant Substances 0.000 claims description 2
- 230000000399 orthopedic effect Effects 0.000 claims description 2
- 229960003975 potassium Drugs 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 239000004332 silver Substances 0.000 claims description 2
- 239000010944 silver (metal) Substances 0.000 claims description 2
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 claims description 2
- 210000005239 tubule Anatomy 0.000 claims description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 abstract description 12
- 210000003298 dental enamel Anatomy 0.000 abstract description 10
- 230000003578 releasing effect Effects 0.000 abstract description 6
- 210000003296 saliva Anatomy 0.000 abstract description 5
- 210000001519 tissue Anatomy 0.000 abstract description 5
- 230000002265 prevention Effects 0.000 abstract description 4
- 229910019142 PO4 Inorganic materials 0.000 abstract description 3
- 238000000265 homogenisation Methods 0.000 abstract description 3
- 230000001376 precipitating effect Effects 0.000 abstract description 3
- 230000002269 spontaneous effect Effects 0.000 abstract description 3
- 239000011575 calcium Substances 0.000 description 30
- 229910052791 calcium Inorganic materials 0.000 description 22
- 229910052698 phosphorus Inorganic materials 0.000 description 20
- 239000006069 physical mixture Substances 0.000 description 20
- 239000000463 material Substances 0.000 description 19
- 239000012890 simulated body fluid Substances 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 238000001556 precipitation Methods 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 229910052710 silicon Inorganic materials 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 238000001878 scanning electron micrograph Methods 0.000 description 8
- 239000013078 crystal Substances 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 description 6
- 238000000634 powder X-ray diffraction Methods 0.000 description 6
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000000120 Artificial Saliva Substances 0.000 description 5
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000000724 energy-dispersive X-ray spectrum Methods 0.000 description 5
- 238000002354 inductively-coupled plasma atomic emission spectroscopy Methods 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- 235000010755 mineral Nutrition 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000004626 scanning electron microscopy Methods 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 4
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- BOTDANWDWHJENH-UHFFFAOYSA-N Tetraethyl orthosilicate Chemical compound CCO[Si](OCC)(OCC)OCC BOTDANWDWHJENH-UHFFFAOYSA-N 0.000 description 4
- 230000000975 bioactive effect Effects 0.000 description 4
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical group [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 3
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 3
- 230000033558 biomineral tissue development Effects 0.000 description 3
- 229960005069 calcium Drugs 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229910052681 coesite Inorganic materials 0.000 description 3
- 229910052906 cristobalite Inorganic materials 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 229910000397 disodium phosphate Inorganic materials 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 239000002159 nanocrystal Substances 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000001144 powder X-ray diffraction data Methods 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000011775 sodium fluoride Substances 0.000 description 3
- 235000013024 sodium fluoride Nutrition 0.000 description 3
- 229910052682 stishovite Inorganic materials 0.000 description 3
- PWYYWQHXAPXYMF-UHFFFAOYSA-N strontium(2+) Chemical compound [Sr+2] PWYYWQHXAPXYMF-UHFFFAOYSA-N 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 229910052905 tridymite Inorganic materials 0.000 description 3
- ZHJGWYRLJUCMRT-UHFFFAOYSA-N 5-[6-[(4-methylpiperazin-1-yl)methyl]benzimidazol-1-yl]-3-[1-[2-(trifluoromethyl)phenyl]ethoxy]thiophene-2-carboxamide Chemical compound C=1C=CC=C(C(F)(F)F)C=1C(C)OC(=C(S1)C(N)=O)C=C1N(C1=C2)C=NC1=CC=C2CN1CCN(C)CC1 ZHJGWYRLJUCMRT-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 239000004135 Bone phosphate Substances 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 239000005312 bioglass Substances 0.000 description 2
- 238000001354 calcination Methods 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000001013 cariogenic effect Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000013081 microcrystal Substances 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000006911 nucleation Effects 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000001508 potassium citrate Substances 0.000 description 2
- 229960002635 potassium citrate Drugs 0.000 description 2
- 235000011082 potassium citrates Nutrition 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000005204 segregation Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002411 thermogravimetry Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 241001286462 Caio Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229910002483 Cu Ka Inorganic materials 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 101100365384 Mus musculus Eefsec gene Proteins 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 229910002808 Si–O–Si Inorganic materials 0.000 description 1
- WJEIYVAPNMUNIU-UHFFFAOYSA-N [Na].OC(O)=O Chemical compound [Na].OC(O)=O WJEIYVAPNMUNIU-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002053 acidogenic effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical compound [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 description 1
- 229910000387 ammonium dihydrogen phosphate Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000032770 biofilm formation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 1
- 229940052299 calcium chloride dihydrate Drugs 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- QNEFNFIKZWUAEQ-UHFFFAOYSA-N carbonic acid;potassium Chemical compound [K].OC(O)=O QNEFNFIKZWUAEQ-UHFFFAOYSA-N 0.000 description 1
- 229960000800 cetrimonium bromide Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- KDQPSPMLNJTZAL-UHFFFAOYSA-L disodium hydrogenphosphate dihydrate Chemical compound O.O.[Na+].[Na+].OP([O-])([O-])=O KDQPSPMLNJTZAL-UHFFFAOYSA-L 0.000 description 1
- MQRJBSHKWOFOGF-UHFFFAOYSA-L disodium;carbonate;hydrate Chemical compound O.[Na+].[Na+].[O-]C([O-])=O MQRJBSHKWOFOGF-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000445 field-emission scanning electron microscopy Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000013038 hand mixing Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000011872 intimate mixture Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 235000019837 monoammonium phosphate Nutrition 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- HWPKGOGLCKPRLZ-UHFFFAOYSA-M monosodium citrate Chemical compound [Na+].OC(=O)CC(O)(C([O-])=O)CC(O)=O HWPKGOGLCKPRLZ-UHFFFAOYSA-M 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000000278 osteoconductive effect Effects 0.000 description 1
- 230000002138 osteoinductive effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229940093956 potassium carbonate Drugs 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
- WKZJASQVARUVAW-UHFFFAOYSA-M potassium;hydron;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [K+].OC(=O)CC(O)(C(O)=O)CC([O-])=O WKZJASQVARUVAW-UHFFFAOYSA-M 0.000 description 1
- 239000012254 powdered material Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229940001593 sodium carbonate Drugs 0.000 description 1
- 229940076133 sodium carbonate monohydrate Drugs 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 238000003980 solgel method Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
Definitions
- the present invention refers to a composite material comprising or consisting of amorphous calcium phosphate and bioactive glass and its use as remineralizing agent in dentistry and for bone regeneration.
- dental caries is the most widespread non-communicable disease which affects both industrialized and developing countries.
- the disease results from a prevalence of acidogenic bacteria in the biofilm that permanently colonizes any oral surface.
- These cariogenic bacteria produce organic acids, and the consequence is a lowering of the pH in the microenvironment of teeth surfaces (enamel and dentine), which triggers the dissolution of their mineral component, hydroxyapatite (HA, Caio(P04)e(OH)2).
- HA dissolution is referred to as the “demineralization process” and leads to the formation of dental cavities.
- Demineralization is a reversible process if the damaged tissues are exposed to an oral environment that favors the opposite process, “remineralization”.
- Demineralized enamel is naturally remineralized by the epitaxial growth of residual HA crystals that act as nucleation sites, as saliva provides a supersaturated environment rich of Ca 2+ and PO4 3 " ions.
- remineralization of enamel by saliva alone is seldom achieved. Therefore, it is required the use of an external source of Ca 2+ and PO4 3 " ions to increase ion supersaturation to efficiently prevent demineralization and boost remineralization.
- This is the aim of remineralizing agents, which restore the structure and preserve the mechanical properties of dental hard tissues by releasing Ca 2+ and PO4 3 " ions, [1J mimicking the spontaneous remineralization process induced by saliva.
- ACP is particularly appealing in dentistry due to its ability to release a higher amount of ions in comparison to crystalline calcium phosphates phases.
- Several ACP products are actually marketed for dental remineralization in formulations that are directly applied on tooth surface (i.e. tooth mousses) having a good level of literature evidence for this use (systematic reviews).
- ACP is an unstable material that rapidly transforms into more thermodynamically stable crystalline phases (e.g., HA) in solution or in dry state by reacting with atmospheric water. Due to this instability, use and handling of ACP is difficult, and several additives were studied to stabilize ACP.
- W02020/002517 and WO2016/012452 describe a fluoride-doped amorphous calcium phosphate (F-ACP) stabilized by citrate ions that in aqueous solution gives burst release of Ca 2+ , PO4 3 ; and F’ ions, is able to crystallize into HA when in contact with enamel and dentine, inhibits cariogenic biofilm formation, and shows a strong remineralizing activity.
- F-ACP has been proved, therefore, to be an excellent material for dental remineralization.
- the main limit of all ACP materials is that their burst release lasts for a short timeframe, and thus several applications of the product are needed for a complete remineralization.
- BGs bioactive glasses
- HA-forming ability bioactive (HA-forming ability)
- osteoconductive osteoconductive
- osteoinductive gives a controlled release of bioactive ions in the surrounding environment.
- bioactive glass nanoparticles BGN
- BGN bioactive glass nanoparticles
- BG have found a successful application as remineralizing agents.
- a serious drawback that hinders this application is that BG cannot release a large amount of Ca 2+ and PO4 3 " ions and is not able to perform completely its remineralization function to form HA because it is diluted away by salivary action in a short time before it attaches to dental surfaces.
- the present invention relates to an amorphous calcium phosphate/bioactive glass composite material (ACP/BG).
- ACP/BG amorphous calcium phosphate/bioactive glass composite material
- This composite material possesses both the short-time ion release capability of ACP as well as the long-time ion release of BG and thus (i) efficiently remineralizes damaged enamel, and (ii) induces the formation of a new HA layer onto enamel and dentin surface.
- ACP component has a twofold action: (i) gives a burst ion release for initial HA formation (Ca 2+ , PO4 3 F- as well as Sr 2+ , Mg 2+ , Zn 2+ ) and (ii) acts as nucleation site for HA growth by attaching onto enamel and dentine surface, while the ion-doped BG component provides for a sustained ion release of remineralizing and biologically active ions (e.g., Ca 2+ , PO4 3 ", F; Si 4+ , Sr 2+ , Zn 2+ Mg 2+ ), thereby generating a continuous remineralization.
- remineralizing and biologically active ions e.g., Ca 2+ , PO4 3 ", F; Si 4+ , Sr 2+ , Zn 2+ Mg 2+
- the ACP/BG composite material is obtained by embedding BG particles in a matrix of ACP nanoparticles in order to maximize homogenization between the two components and to produce a composite with high uniformity from the macro- to the nano-scale. This has been achieved with a process that includes a step of precipitating ACP onto BG particles.
- the BG particles can be nano-, micro-, or macro-particles.
- the particles can also be porous or mesoporous
- the invention relates also to the use of the composite material of the invention for use in the prevention of dental demineralization and to boost remineralization.
- the composite material here disclosed is used as remineralizing agent thanks to its ability to restore the structure and preserve the mechanical properties of dental hard tissues by releasing Ca 2+ and PO4 3 " ions, thereby mimicking the spontaneous remineralization process induced by saliva.
- the composite material can also be used for bone regeneration.
- FIG. 1 SEM micrographs of (A) ACP/BG 80/20 composite, (B) 60/40 composite, (C) 40/60 composite, and (D) ACP+BG physical mixture, (E) ACP/MBGN 80/20 composite, (F) 60/40 composite, (G) 40/60 composite, and (H) ACP+MBGN physical mixture. Light grey arrows point at BG or MBGN particles, black arrows at ACP particles.
- FIG. 1 SEM micrograph of (A) ACP/MBGN 80/20, (B) ACP/MBGN 60/20, (C) ACP/MBGN 40/60, (D) pure MBGN, and (E) pure ACP after incubation in SBF for 7 days.
- the composite material of the invention comprises or consists of bioactive glass particles and amorphous calcium phosphate particles as an intimate and homogenous mixture obtained by precipitating ACP onto BG particles.
- BG particles are chosen among macroscopic particles, micrometric particles or nanoparticles. Each of them can be microporous or mesoporous. BG nanoparticles are defined as BGN and mesoporous BG nanoparticles are defined as MBGN.
- Compositions of macro and micrometric BG particles typically contain SiC>2, CaO, Na2 ⁇ D and P2O5 in different ratios.
- Other components e.g., ZnO, CuO, SrO, can also be incorporated in BG compositions.
- Compositions of BGN and MBGN typically contain SiO2 and CaO in different ratios.
- BGN are made of 90% SiO2 and 10% CaO
- MBGN are made of 10% CaO and 90% SiO2.
- Other components e.g., ZnO, CuO, SrO, can also be incorporated into BG nanoparticles and MBGN
- ACP is in the form of nanoparticles.
- ACP is doped with one or more of the following ions: F, Zn, Mg, Sr, Na, K, Fe, Cu, Cl, Ag.
- the composite material comprises ACP in an amount ranging between 1 % wt and 99% wt and BG in an amount ranging from 99% wt and 1 % wt.
- the composite material comprises ACP in amount ranging between 20% and 80%, or 20% and 60%, or 20% and 40% and BG in an amount ranging from 80% and 20%, or 60% and 20%, or 40% and 20%.
- the two components are intimately and homogenously intertwined together to yield the superior properties demonstrated by the composite material with respect to a simple mixture of the two components ACP and BG.
- the composite material bypasses the intrinsic disadvantages that its constituting components have, such as poor ion release on the short timeframe, limited apatite formation, and no fluoride release for BG, and no sustained release and low stability for ACP.
- the composite material is obtained with a process that comprises the following steps: a) Mixing an aqueous solution comprising a calcium salt and/or calcium hydroxide, BG particles and a sodium or potassium citrate salt and/or citric acid (solution A) with a solution comprising a phosphate salt and/or phosphoric acid and a carbonate salt and/or carbonic acid (solution B); b) Stirring the mixture for at least 3 seconds to allow the formation of a precipitate; c) Collecting and drying the precipitate.
- the calcium salt is chosen among calcium chloride, calcium nitrate, calcium acetate, calcium lactate, calcium oxalate, calcium citrate, and calcium sulfate,
- the sodium or potassium citrate salt is chosen among sodium citrate tribasic, sodium citrate dibasic, sodium citrate monobasic, potassium citrate tribasic, potassium citrate dibasic, and potassium citrate monobasic.
- the phosphate salt is chosen among sodium phosphate, sodium hydrogen phosphate, sodium dihydrogen phosphate, or potassium phosphate, potassium hydrogen phosphate, potassium dihydrogen phosphate, or ammonium phosphate, ammonium hydrogen phosphate, ammonium dihydrogen phosphate.
- the carbonate salt is chosen among sodium carbonate, sodium hydrogen carbonate, sodium dihydrogen carbonate, or potassium carbonate, potassium hydrogen carbonate, potassium dihydrogen carbonate, or ammonium carbonate, ammonium hydrogen carbonate, ammonium dihydrogen carbonate.
- step b) The mixture is stirred in step b) for a time of 3 sec-1 h, preferably 10 sec-60 sec.
- BG particles which can be BG macro or microparticles, BGN or MBGN are prepared with methods known in the art or are commercially available.
- solution A can be optionally sonicated to disperse the BG particles and the pH of solution B can be optionally brought to a basic pH of above 9.
- the amount of BG particles used can be varied to yield a final ACP:BG weight ratio of between 80:20, 60:40, or 40:60 for example.
- Solution B can optionally include fluorine, and/or chlorine ions that are doping agents for ACP.
- the mixing step a) is preferably performed at a temperature between 1-30°C, or 4-25°C, or 20-25°C.
- the composite material obtained by the process of the invention has a structure in which the BG particles are surrounded and immersed in a matrix of ACP nanoparticles. There is no segregation between ACP and BG and the mixture is homogenous and intimately mixed, forming a deeply-intertwined composite.
- a comparison between the composite of the invention and a physical mixture of ACP and BG show that the physical mixture is not homogenous, presenting micrometric granules of pure BGN/MBGN or pure ACP.
- the composite of the invention has shown a good release of Ca, P, Si and optionally F, Zn and/or Mg, if doped with one or more of those ions.
- the release is more intense for a first period of at least 2 h and remains sustained for a second period of up to 5 h. Afterwards the release gradually slows down continuing as a slow release up to 24 hours.
- the release curves have been compared to pure ACP, which shows only a burst release of Ca, P, and F in less than 2 h, and to pure BG, whose release of Ca, P, and Si is less intense and is spread across the 24 h timeframe.
- ACP/BG composites their release is intermediate between the ones of pure ACP and pure BG and depends on ACP:BG ratio, i.e. ACP-rich composites have a more intense Ca, P, and F release and less intense Si release, while in BG-rich composites the behavior is the opposite.
- ACP:BG ratio i.e. ACP-rich composites have a more intense Ca, P, and F release and less intense Si release, while in BG-rich composites the behavior is the opposite.
- ACP:BG ratio The most important finding is that ACP/BG composite has a stronger Ca, P, and F release and a weaker Si release than the ACP+BG physical mixture with identical weight ratio. This is the definitive proof that the composite preparation gives better ion-releasing properties which cannot be achieved by only mixing the two base ingredients.
- the composite of the invention can also be used to achieve dentin desensitization by occluding the dentinal tubules.
- Another use of the composite of the invention is for bone regeneration.
- the composite material can also be used for bone regeneration. Owing to its outstanding remineralization and ion release capacity, the composite material can be used as bone defect filler to accelerate formation of HA and stimulate osteogenesis and angiogenesis.
- the composite material can also be used to fabricate orthopedic implant coating or bone tissue engineering scaffolds for bone repair and regeneration. The fast release of Ca 2+ and PO4 3 " ions from ACP facilitates bone bonding while sustained release of biologically active ions from BGs ensures favorable biological responses for bone regeneration.
- the invention refers also to a method to prevent dental demineralization and/or to boost dental remineralization which includes a step of applying the composite material on dental hard tissues.
- Calcium chloride dihydrate (CaCl2-2H2O, >99.0% pure), hydrochloric acid (HCI, >37.0% pure), sodium citrate tribasic dihydrate (Na3(C6H5O7) 2H2O, >99.0% pure, hereafter called sodium citrate), sodium phosphate dibasic dihydrate (Na2HPO4-2H2O, >99.0% pure), sodium carbonate monohydrate (Na2CO3-2H2O, >99.0% pure), sodium fluoride (NaF, >99.0% pure), MBGN, BGN, BG. MBGN were synthesized and characterized as reported by Zheng et al. [3] using a microemulsion-based sol-gel method.
- TEOS tetraethyl orthosilicate
- VWR calcium nitrate tetrahydrate
- BGN nanoparticles were synthesized using a modified Stober method (Zheng K, et al. Timing of calcium nitrate addition affects morphology, dispersity and composition of bioactive glass nanoparticles[J], RSC advances, 2016, 6(97): 95101 -95111 ).
- a solution (A) composed of 2.25 mL of tetraethyl orthosilicate (TEOS, 98%, Sigma-Aldrich) and in 25 mL of ethanol (96% VWR) was mixed with Solution B that was prepared by mixing 4.5 mL of ammonium hydroxide solution (28.0- 30.0%, Sigma-Aldrich), 8.12 mL of ethanol and 12.38 mL of deionized water. After leaving the reaction to proceed for 30 min, 1.45 g of calcium nitrate tetrahydrate was added. The mixtures were allowed to react for a further 90 min before collection by centrifugation at 7197 ref for 25 min.
- TEOS tetraethyl orthosilicate
- the obtained particles were dispersed and washed twice with deionized water and once with ethanol.
- the collected particles were subsequently dried at 60 °C overnight before calcination at 700 °C for 2 h with a heating rate of 2 °C/min.
- ACP/BG composites were prepared by mixing at room temperature equal volumes of two aqueous solutions, consisting of (A) 100 mM CaCl2 + 100 mM sodium citrate + X mg/mL BG (either BG, BGN, or MBGN) and (B) 120 mM Na 2 HPO 4 + 200 mM Na 2 CO 3 + 50 mM NaF.
- solution (A) was sonicated at 20% amplitude for 3 min with a pulsation of 5 s under ice cooling employing a Vibracell VCX 500 tip sonicator (SONICS, Newtown, CT, USA) to disperse BG, while the pH of solution (B) was brought to 9.5 with HCI 37 wt.%.
- the precipitate was left to stir for at least 30 s at room temperature and afterwards the particles were collected by centrifugation (7000 RPM, 5 min, 4 °C) and repeatedly washed with ultrapure water. Finally, the materials were freeze-dried for 24h.
- the 60:40 wt.% ACP+BG physical mixture was prepared by hand mixing together 240 mg of ACP powder and 160 mg of BG powder (either BG, BGN, or MBGN) until complete homogeneity was achieved.
- Powder X-ray diffraction PXRD: PXRD patterns of the samples were recorded on a D8 Advance diffractometer (Broker, Düsseldorf, Germany) using Cu Ka radiation generated at 40 kV and 40 mA. PXRD patterns were collected in the 10 - 60° 29 range with a step size of 0.02 degree and a collection time of 0.5 s.
- FT-IR Fourier transform infrared spectroscopy
- SSABET Specific Surface Area analysis
- Thermal characterization Thermogravimetry analysis (TGA) of the samples was performed with a STA 449F3 Jupiter instrument (Netzsch GmbH, Selb, Germany). 10 mg of the samples were placed in an alumina crucible and an empty crucible was used as a reference. The crucibles were heated from room temperature to 1100 °C with a heating rate of 10 °C/min under air flow.
- SEM Scanning electron microscopy
- sample powders were dispersed into 10mL of artificial saliva prepared as modified Tani-Zucchi solution containing KCI 20mM, KSCN 5.3mM, Na2HPO4 1.4mM, NaHCOs 15mM, and lactic acid 10mM.
- the suspension was maintained at 37 °C under shaking.
- 8m L of the supernatant that was separated from the solid phase by centrifugation at 7000 rpm for 5m in
- ICP-OES and fluoride ion selective electrode was removed for ions quantification by ICP-OES and fluoride ion selective electrode. After that, samples were rinsed with 8m L of fresh artificial saliva, and the suspension was again shacked at 37 °C until the next time point.
- ICP-OES inductively-coupled plasma optical emission spectrometry
- ICP-OES ion-selective electrode for fluoride
- ICP-OES was performed with an Agilent 5100 instrument (Agilent Technologies, Santa Clara, CA, USA), while ISEF was an Intellical ISEF121 electrode (Hach Lange, Loveland, CO, USA).
- the supernatants were diluted 1 :3 with a 1 wt. % HNOs aqueous solution.
- F analyses were performed as suggested by instrument manufacturer. Standard fluoride solutions were prepared from a certified standard (1 ,000 ppm F certified standard, Sigma Aldrich, St. Luis, MO, United States); the calibration curve was then obtained by analyzing the standard solutions on the same day they were prepared.
- the pellet was washed with ultrapure water and freeze-dried. Afterward, the dried materials were analyzed by PXRD, SEM, and SEM-EDS as reported above.
- ACP+BG physical mixtures are not homogeneous, presenting micrometric granules of pure BGN/MBGN or pure ACP ( Figure 1 H). In some granules it is possible to observe a mixture of MBGN and FACP particles, but it is likely that the mixing occurred only on the surface of granules.
- compositions are similar to the nominal ones, although that with 20/80 sample for MBGN is rich in MBGN component (20/80) while with BG there is less excess of BG (40/60).
- ACP/MBGN 60/40 55/45 ⁇ 5 ACP/BG 60/40 60/40 ⁇ 5
- Ca/Si and P/Si ratios decrease when MBGN is increased, as expected.
- Ca/P molar ratio of 20/80 composite (1.82) is close to ACP Ca/P value (ca. 1.80) as ACP is the dominant component in the composite, while in composites with higher MBGN content the Ca/P ratio increases to ca. 2-4 because also MBGN contains calcium.
- the SEM-EDS spectra of ACP+MBGN physical mixtures varies greatly depending on the sampled region, passing from a Si-rich composition for BG granules to a CaP-rich composition for ACP ones.
- the high SSABET values of pure MBGN and ACP are due to their extensive micro- and meso-porosities [3, 5].
- the ACP+MBGN physical mixture has a higher SSABET than the corresponding composite (220 vs 163 m 2 g’ 1 , respectively), which is another proof that the same particle homogenization cannot be achieved through simple mixing.
- ACP/MBGN 20/80 sample its SSABET (284 ⁇ 28 m 2 g -1 ) is similar to the SSABET of pure MBGN.
- the FT-IR spectra of the composites gives a further confirmation about their nature (Figure 2C,D).
- the main IR bands correspond either to phosphate groups in an amorphous environment (vs, vi, and V4PO4 modes as broad bands at 1010, 960, and 555 cm -1 , respectively) or silicate groups (Si-O-Si stretching, bending, and rocking modes at 1075, 800, and 450 cm -1 , respectively) [8, 9],
- the relative intensity of all these bands is correlated to the ACP:BG ratio and shift accordingly.
- the key tests to evaluate remineralization capability of ACP/BG composites were (i) their ion release in an acidic artificial saliva that mimics a carious oral environment (modified Tani-Zucchi solution), and (ii) their capability to induce HA crystallization when are in contact with simulated body fluid.
- ACP/BG composites their release is intermediate between the ones of pure ACP and BG and depends on ACP:BG ratio, i.e. ACP-rich composites have a more intense Ca, P, and F release and less intense Si release, while in BG-rich composites the behavior is the opposite ( Figure 3A-D).
- ACP/BG 60:40 composite has a stronger Ca, P, and F release and a weaker Si release than the ACP+BG physical mixture with identical weight ratio. This is the definitive proof that the composite preparation gives better ion-releasing properties which cannot be achieved by only mixing the two base ingredients.
- the other key test to evaluate remineralization capability of ACP/BG composites is the assessment of their capability to induce HA crystallization when are in contact with simulated body fluid (SBF) by the simultaneous (i) crystallization of ACP into HA as well as (ii) the precipitation of calcium and phosphate ions contained in SBF into new mineral by interaction with ACP/BG.
- SBF simulated body fluid
- the amount of precipitated ions is directly proportional to ACP:BG ratio, while Si release is inversely proportional to it. After three days of incubation all phosphate in solution has been consumed, while only a part of Ca and Mg have been removed.
- ACP/MBGN composites in SBF is controlled by ACP:BG ratio.
- Ca, Mg, and P data suggest that all composites induce the precipitation of a Mg-doped calcium phosphate phase until all P in solution has been consumed, and the precipitation is faster for ACP and ACP-rich composites.
- BG immersed in SBF induce the formation of HA while ACP converts into HA, therefore the new crystals observed in the composites are HA nanocrystals formed ion release and reprecipitation given by both MBGN and ACP (thicker needle crystals), as well as by ACP direct conversion (thinner needle crystals).
- ACP component controls HA formation kinetics, and induces the formation of new HA nanocrystals in proportion to ACP:MBGN weight ratio.
Abstract
L'invention concerne un matériau composite de phosphate de calcium amorphe/verre bioactif (ACP/BG). Ce matériau composite possède à la fois l'aptitude à la libération d'ions à court terme du ACP et à la libération d'ions à long terme du BG et ainsi (i) reminéralise efficacement l'émail endommagé et (ii) induit la formation d'une nouvelle couche d'HA sur l'émail et la surface de dentine. Le matériau composite d'ACP/BG est obtenu par incorporation de particules de BG dans une matrice de nanoparticules d'ACP afin de maximiser l'homogénéisation entre les deux constituants et de produire un composite présentant une uniformité élevée à partir de l'échelle macrométrique à l'échelle nanométrique. Ceci a été obtenu par un procédé qui comprend une étape de précipitation d'ACP sur des particules de BG. Les particules de BG peuvent être des nanoparticules, des microparticules ou des macroparticules. Les particules peuvent également être poreuses ou mésoporeuses. L'invention concerne également l'utilisation du matériau composite de l'invention pour une utilisation dans la prévention de la déminéralisation dentaire et pour stimuler la reminéralisation. En d'autres termes, le matériau composite divulgué ici est utilisé en tant qu'agent de reminéralisation grâce à son aptitude à restaurer la structure et à préserver les propriétés mécaniques de tissus dentaires durs par la libération d'ions Ca2+ et PO43−, imitant ainsi le processus de reminéralisation spontanée induit par la salive. Le matériau composite peut également être utilisé pour la régénération osseuse.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102022000026496 | 2022-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024134524A1 true WO2024134524A1 (fr) | 2024-06-27 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9205035B2 (en) | Ion substituted calcium phosphate particles | |
Landi et al. | Biomimetic Mg-substituted hydroxyapatite: from synthesis to in vivo behaviour | |
Rameshbabu et al. | Synthesis of nanocrystalline fluorinated hydroxyapatite by microwave processing and its in vitro dissolution study | |
US7670579B2 (en) | Nanostructured bioactive materials prepared by dual nozzle spray drying techniques | |
Mardziah et al. | Strontium-doped hydroxyapatite nanopowder via sol-gel method: effect of strontium concentration and calcination temperature on phase behavior | |
US7390335B2 (en) | Nanostructured bioactive materials prepared by spray drying techniques | |
Kim et al. | Sol–Gel Preparation and Properties of Fluoride‐Substituted Hydroxyapatite Powders | |
EP3177273A1 (fr) | Procédé pour obtenir des nanoparticules de phosphate de calcium amorphe revêtues de citrate dopées au fluorure | |
Kazuz et al. | α-Tricalcium phosphate/fluorapatite based composite cements: Synthesis, mechanical properties, and biocompatibility | |
Kalbarczyk et al. | Potential biomedical application of calcium phosphates obtained using eggshells as a biosource of calcium at different initial pH values | |
Degli Esposti et al. | Composite materials of amorphous calcium phosphate and bioactive glass nanoparticles for preventive dentistry | |
CN112384187B (zh) | 掺杂氟离子的稳定化无定形磷酸钙以及用于产生其的工艺 | |
WO2024134524A1 (fr) | Matériau composite à base de verre bioactif et de phosphate de calcium amorphe et procédé pour sa production | |
Xie et al. | Calcium phosphate dental cements | |
Cahyanto et al. | Enamel remineralization effect using dewaxed shellac varnishes with added carbonate apatite and tricalcium phosphate | |
Okada et al. | Adsorption and desorption behaviors of cetylpyridinium chloride on hydroxyapatite nanoparticles with different morphologies | |
Koc | Synthesis and characterization of strontium and chlorine co-doped tricalcium phosphate | |
Bogdanova et al. | Synthesis and study of nanosized biomaterials based on hydroxyapatite | |
Alyousef et al. | Mashael Abdullah Benrahed 1, Abdul Samad Khan 2, Saroash Shahid3 1College of Dentistry, Imam Abdulrahman Bin Faisal University, Dammam, Eastern Province, Saudi Arabia; 2Department of Restorative Dental Sciences, College of Dentistry, Imam Abdulrahman Bin Faisal University, Dammam, Eastern Province, Saudi Arabia | |
RO133124B1 (ro) | Nanomateriale pe bază de hidroxiapatită multisubstituită şi procedeu de obţinere a acestora | |
Mohammadi et al. | Comparative Study of in-vitro Behavior of Tetracalcium Phosphate-based Cement: Ringer’s Solution versus Human Blood Plasma | |
PL229920B1 (pl) | Sposób wytwarzania nanokrystalicznych czystych hydroksyapatytów Ca₁₀(PO₄)₆(OH)₂ |